ANI Pharmaceuticals (ANIP) vs Zenas BioPharma (ZBIO)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Zenas BioPharma (ZBIO) has outperformed ANI Pharmaceuticals (ANIP) over the past year, gaining 1.3% versus a loss of 21.5%. Zenas BioPharma is the larger company by market cap ($1.78 billion vs $1.68 billion), about 1.1 times the size. ANI Pharmaceuticals converts more of its revenue into profit, with a net margin of 8.9% versus -3777.4%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ANIP | ZBIO |
|---|---|---|
| Share price | $73.16 | $27.28 |
| Market cap | $1.68B | $1.78B |
| 1-day change | +1.64% | +3.96% |
| YTD return | -8.82% | -27.73% |
| 1-year return | -21.46% | +1.31% |
| 5-year return | +86.77% | — |
| P/E ratio (TTM) | 15.84 | — |
| Forward P/E | 7.20 | — |
| EPS (TTM) | $4.62 | $-9.63 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $883.37M | $10.00M |
| Revenue growth (YoY) | +43.78% | +100.00% |
| Net income (latest FY) | $78.34M | $-377.74M |
| Gross margin | 61.36% | — |
| Operating margin | 12.58% | -3830.57% |
| Net margin | 8.87% | -3777.37% |
| 52-week high | $97.00 | $44.60 |
| 52-week low | $69.58 | $13.50 |
| Distance from 52-week high | -24.58% | -38.83% |
| Analyst consensus | buy | strong_buy |
| Avg. price target upside | +44.59% | +75.51% |
| Average volume | 374.47K | 733.34K |
| Shares outstanding | 22.96M | 65.18M |
| Employees | 970 | 167 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- ZBIO has outperformed ANIP by 22.8 percentage points over the past year.
- ANI Pharmaceuticals is more profitable, keeping 8.9 cents of every revenue dollar as net income versus -3777.4 cents for Zenas BioPharma.
- Zenas BioPharma grew revenue faster in its latest fiscal year (+100.00% vs +43.78%).
About ANI Pharmaceuticals
ANIP stock →ANI Pharmaceuticals, Inc., a biopharmaceutical company, develops, manufactures, and markets branded and generic pharmaceutical products in the United States and internationally. The company provides injectables, softgel capsules, and Cortrophin gel, as well as ILUVIEN and YUTIQ products.
Health Care · Biotechnology: Pharmaceutical Preparations · 970 employees
About Zenas BioPharma
ZBIO stock →Zenas BioPharma, Inc., a clinical-stage biopharma company, engages in the development and commercialization of transformative immunology-based therapies. Its lead product candidate is obexelimab, a bifunctional monoclonal antibody designed to bind CD19 and Fc?RIIb for the treatment of various I&I diseases and various indications, including immunoglobulin G4-related disease, multiple sclerosis, and systemic lupus erythematosus.
Health Care · Biotechnology: Pharmaceutical Preparations · 167 employees
ANIP vs ZBIO FAQ
Which is bigger, ANI Pharmaceuticals or Zenas BioPharma?
Zenas BioPharma (ZBIO) is larger, with a market capitalization of $1.78B compared with $1.68B for ANI Pharmaceuticals (ANIP).
Which stock has performed better over the past year, ANIP or ZBIO?
ZBIO returned +1.31% over the past 12 months, compared with -21.46% for ANIP (price return, excluding dividends). Past performance does not predict future results.
Are ANI Pharmaceuticals and Zenas BioPharma in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.